Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2206945 | 0.93 | SMN1; SMN2 (0.46) | USP2SMN1; SMN2TSHRALOX15KDM4E | |
| SCHEMBL24940829 | 0.92 | USP2 (0.38) | USP2SMN1; SMN2TSHRALOX15KDM4E | |
| SCHEMBL7847096 | 0.88 | TSHR (0.47) | SMN1; SMN2TSHRKDM4EL3MBTL1ATM | |
| SCHEMBL25737087 | 0.87 | USP2 (0.42) | USP2SMN1; SMN2TSHRALOX15KDM4E | |
| SCHEMBL15958599 | 0.87 | USP2 (0.42) | USP2SMN1; SMN2TSHRALOX15KDM4E | |
| SCHEMBL24940831 | 0.87 | USP2 (0.41) | USP2SMN1; SMN2TSHRALOX15L3MBTL1 | |
| SCHEMBL425879 | 0.85 | USP2 (0.38) | USP2SMN1; SMN2TSHRKDM4EPKM | |
| SCHEMBL2815082 | 0.85 | USP2 (0.40) | USP2SMN1; SMN2TSHRALOX15L3MBTL1 | |
| SCHEMBL17113616 | 0.85 | SMN1; SMN2 (0.43) | USP2SMN1; SMN2TSHRALOX15L3MBTL1 | |
| SCHEMBL6992779 | 0.84 | USP2 (0.42) | USP2SMN1; SMN2TSHRALOX15L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3092229-B1 | PYRROLIDINYL SULFONE DERIVATIVES AND THEIR USE AS ROR GAMMA MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2018-03-28 | — | — | EP | disclosed |
| EP-3092229-A1 | PYRROLIDINYL SULFONE DERIVATIVES AND THEIR USE AS ROR GAMMA MODULATORS | Bristol-Myers Squibb Company (US) | 2016-11-16 | — | — | EP | disclosed |
| US-20160326108-A1 | PYRROLIDINYL SULFONE DERIVATIVES AND THEIR USE AS ROR GAMMA MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2016-11-10 | — | — | US | disclosed |
| US-9458171-B2 | Pyrrolidinyl sulfone RORγ modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-04 | — | — | US | disclosed |
| US-20150191483-A1 | PYRROLIDINYL SULFONE RORGAMMA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-07-09 | — | — | US | disclosed |
| WO-2015103509-A1 | PYRROLIDINYL SULFONE DERIVATIVES AND THEIR USE AS ROR GAMMA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-07-09 | — | — | WO | disclosed |
| EP-2170850-B1 | NOVEL DICARBOXYLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS | BIOPROJET SOC CIV (FR) | 2014-09-24 | — | — | EP | disclosed |
| EP-2170850-B1 | NOVEL DICARBOXYLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS | BIOPROJET SOC CIV (FR) | 2014-09-24 | — | — | EP | disclosed |
| US-8809539-B2 | Dicarboxylic acid derivatives as S1P1 receptor agonists | BIOPROJET (FR) | 2014-08-19 | — | — | US | disclosed |
| US-8809539-B2 | Dicarboxylic acid derivatives as S1P1 receptor agonists | BIOPROJET (FR) | 2014-08-19 | — | — | US | disclosed |
| WO-2012172043-A1 | PURINE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS FOR PREVENTION OR TREATMENT OF BACTERIAL INFECTIONS | LABORATOIRE BIODIM (FR) | 2012-12-20 | — | — | WO | disclosed |
| US-20120040897-A1 | NOVEL DERIVATIVES OF ACYL CYANOPYRROLIDINES | SUN PHARMA ADVANCED RESEARCH COMPANY LTD. (IN) | 2012-02-16 | — | — | US | disclosed |
| EP-2305660-A1 | New thiadiazole derivatives | Almirall, S.A. (ES) | 2011-04-06 | — | — | EP | disclosed |
| WO-2011035900-A1 | NEW THIADIAZOLE DERIVATIVES | ALMIRALL, S.A. (ES) | 2011-03-31 | — | — | WO | disclosed |
| US-20100249187-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS | BIOPROJET (FR) | 2010-09-30 | — | — | US | disclosed |
| CN-101784535-A | Novel dicarboxylic acid derivatives as S1P1 receptor agonists | BIOPROJET SOC CIV | 2010-07-21 | — | — | CN | disclosed |
| EP-2170850-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS | BIOPROJET (FR) | 2010-04-07 | — | — | EP | disclosed |
| EP-2014653-A1 | Novel dicarboxylic acid derivatives as S1P1 receptor agonists | BIOPROJET (FR) | 2009-01-14 | — | — | EP | disclosed |
| WO-2008152149-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS | BIOPROJET (FR) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040897-A1 | NOVEL DERIVATIVES OF ACYL CYANOPYRROLIDINES | NR1D2, STARD10, NR1D1 | USP2 4772/4885SMN1; SMN2 3251/4885TSHR 1358/4885 |
| US-20100249187-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS | S1PR1, S1PR2, S1PR5 | USP2 4600/4885SMN1; SMN2 3276/4885TSHR 1549/4885 |
| US-20160326108-A1 | PYRROLIDINYL SULFONE DERIVATIVES AND THEIR USE AS ROR GAMMA MODULATORS | RORC, RORB, RORA | USP2 3493/4885SMN1; SMN2 1758/4885TSHR 503/4885 |
| US-20150191483-A1 | PYRROLIDINYL SULFONE RORGAMMA MODULATORS | RORC, RORB, RORA | USP2 3646/4885SMN1; SMN2 1871/4885TSHR 538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.